Costimulatory molecules B7-1 and B7-2 on CSF cells in multiple sclerosis and optic neuritis

Journal of Neuroimmunology

Volumn 96, Issue 1, 1999, Pages 112-120

  Windhagen, Anja ^a   Maniak, Susanna ^a   Gebert, Andreas ^a   Ferger, Isabel ^a   Heidenreich, Fedor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Costimulatory molecules; CSF cells; Immunohistochemistry; Multiple sclerosis; Optic neuritis

Indexed keywords

CYTOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOCYTE; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CEREBROSPINAL FLUID; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MONOCYTES; MULTIPLE SCLEROSIS; OPTIC NEURITIS;

EID: 0033119005     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00012-0     Document Type: Article

References (44)

1. Anderson A., Alvarez-Cermeno J.et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. 57:1994;897-902.
2. Armor S., Baker D.et al. Multiple sclerosis: variations on a theme. Immunol. Today. 18:1997;368-371.
3. Balashov K., Smith D.et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. U.S.A. 94:1997;599-603.
4. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis. Ann. Neurol. 37:1995;424-435.
5. Caux C., Vanbervliet B.et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180:1994;1841-1847.
6. Corona-Vasquez T., Ruiz-Sandoval J.et al. Optic neuritis progressing to multiple sclerosis. Acta Neurol. Scand. 95:1997;85-89.
7. Cross A.H., Girard T.J.et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:1995;2783-2789.
8. Cuzner M.L., Hayes G.M.et al. The nature of inflammatory components during demyelination in multiple sclerosis. J. Neuroimmunol. 20:1988;203-209.
9. deSimone R., Giampaolo A.et al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J. Neuropathol. Exp. Neurol. 54:1995;175-187.
10. Dore-Duffy P., Newman W.et al. Circulating, soluble adhesion proteins in CSF and serum of patients with multiple sclerosis: correlation with clinical activity. Ann. Neurol. 37:1995;55-62.
11. D'Souza S., Bonetti B.et al. Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:1996;2361-2370.
12. Engel P., Gribben J.et al. The B7-2 B70 costimulatory molecule expressed by monocytes and activated B-lymphocytes is the CD86 differentiation antigen. Blood. 84:1994;1402-1407.
13. Freeman G., Borriello F.et al. Uncovering the functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science. 3:1993;1-2.
14. Freeman G.J., Boussiotis V.A.et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially stimulates the initial production of IL-4. Immunity. 2:1995;523-532.
15. Freeman G., Cardoso A.et al. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80) resolving the question regarding a third CD28/CTLA4 counter-receptor. J. Immunol. 161:1998;2708-2715.
16. Genç K., Dona D.et al. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon b-1b therapy. J. Clin. Invest. 99:1997;2664-2671.
17. Gimmi C.D., Freeman G.J.et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6586.
18. Gold R., Hartung H.et al. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. 20:1997;399-404.
19. Guerder S., Meyerhoff J.et al. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity. 1:1994;155-166.
20. Hafler D.A., Weiner H.L. In vivo labelling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann. Neurol. 22:1987;89-93.
21. Harlan D.M., Hengartner H.et al. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3137-3141.
22. Hartung H., Reiners K.et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:1995;186-193.
23. Khoury S.J., Akalin E.et al. CD28-B7 costimulatory blockade by CTLA4-Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155:1995;4521-4524.
24. Kivisäkk P., Tian W.et al. Optic neuritis and cytokines. Neurology. 50:1998;217-223.
25. Koch N., Moldenhauer G.et al. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J. Immunol. 147:1991;2643-2651.
26. Kuchroo V.K., Prabhu Das M.et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
27. Lenschow D.J., Zeng Y.et al. Long-term survival of xenogenic pancreatic islet grafts induced by CTLA4-Ig. Science. 257:1992;789. Washington, DC.
28. Lenschow D.J., Ho S.C.et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1995;1145-1155.
29. Linsley P.S., Wallace P.M.et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 257:1992;792. Washington, DC.
30. Linsley P.S., Greene J.L.et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but different kinetics to CD28 and CTLA-4 receptors. Immunity. 1:1994;793-801.
31. Oehmichen M., Domasch D.et al. Origin, proliferation and fate of cerebrospinal fluid cells. J. Neurol. 227:1982;145-150.
32. Ozawa K., Suchanek G.et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 117:1994;1311-1322.
33. Racke M.K., Scott D.E.et al. Distinct roles for B7-1(CD80) and B7-2(CD86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96:1995;2195-2203.
34. Rieckmann P., Albrecht M.et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
35. Rieckmann P., Altenhofen B.et al. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann. Neurol. 41:1997;326-333.
36. Sellebjerg F., Jensen J.et al. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J. Neuroimmunol. 84:1998;179-187.
37. Soderstrom M., Ya-Ping J.et al. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF and HLA findings. Neurology. 50:1998;708-714.
38. Storch M., Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 10:1997;186-192.
39. Svenningsson A., Dotevall L.et al. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J. Neuroimmunol. 75:1997;59-68.
40. Tan P., Anasetti C.et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177:1993;165-173.
41. The Optic Neuritis Study Group The 5-year risk of MS after optic neuritis. Neurology. 49:1997;1404-1413.
42. Thomas R., Beuche W.et al. The proliferation rate of T and B lymphocytes in cerebrospinal fluid. J. Neurol. 238:1991;27-30.
43. Turka L.A., Linsley P.S.et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. U.S.A. 89:1992;11102.
44. Windhagen A., Newcombe J.et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1995;1-12.